查詢結果分析
相關文獻
- Bevacizumab的安全性分析報告
- 黃斑部病變的神奇藥物療法--抗血管內皮細胞生長因子眼球內注射
- 藥物代謝、交互作用與副作用
- 選擇性血清素再吸收抑制劑
- Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Healthy Adolescents on Two-dose Schedule
- Effect of Local Massage on Vaccination: DTP and DTPa
- 飼料添加物(劑)的使用及意外副作用
- 飼料添加物(劑)的使用及意外副作用
- 對於藥物副作用(臨床安全性)報告的看法
- Warfarin 之副作用
頁籤選單縮合
題 名 | Bevacizumab的安全性分析報告=A Safety Study of Bevacizumab Therapy |
---|---|
作 者 | 林季伶; 李冠德; 鄭奕帝; | 書刊名 | Medical Journal of South Taiwan |
卷 期 | 3:2 2007.09[民96.09] |
頁 次 | 頁84-91 |
分類號 | 418.31 |
關鍵詞 | VEGF; 血管內皮細胞生長因子; 副作用; 胃腸穿孔; Bevacizumab; Vascular endothelial growth factor; Adverse effects; Bowel perforation; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:了解Bevacizumab在安全性上的使用情形。Bevacizumab是一個抑制血管新生的新藥,其結合到血管內皮細胞生長因子(vascular endothelial growth factor; VEGF)並抑制其活性,其安全性在近期引起高度的關注。方法:本研究方法採取前瞻性縱向研究方法(prospective longitudinal study),評估期間從2004年11月至2006年6月,對象是住院期間或門診接受Bevacizumab合併化學治療的病人。副作用的嚴重程度乃依據美國國家癌病協會(National Cancer Institute)所頒布之CTCAE標準(Common Terminology Criteria for Adverse Events, v3.0)。結果:本研究共納入27位病人,其中大腸癌13人、直腸癌8人、肝癌5人、闌尾癌1人。化療引起之嚴重副作用,包括感染、腸穿孔、高血壓、嗜中性白血球低下、貧血、febrile neutropenia、黏膜炎、神經病變、胃潰瘍/十二指腸潰瘍、出血等,其中兩位腸穿孔病例死亡。結論:本研究顯示與bevacizumab有關的副作用是高血壓、蛋白尿、胃潰瘍/十二指腸潰瘍、嚴重出血與腸穿孔,並未有發生血栓栓塞的案例。 |
英文摘要 | Purpose: To assess the rate of side effects during treatment with the antivascular endothelial growth factor monoclonal antibody bevacizumab. Methods: We performed a prospective longitudinal study from our institutional database. Adverse events were categorized according to the Common Terminology Criteria of the National Cancer Institute, version 3.0. Results: A total of 27 patients started treatment with bevacizumab from November 2004 to January 2006. Serious side effects associated with chemotherapy included infection, bowel perforation, hypertension, neutropenia, anemia, febrile neutropenia, mucositis, neuropathy, gastric ulcer/duodenal ulcer and severe bleeding. Two patients presented with severe bowel perforation and died later as a consequence of their septic condition. Conclusion: This analysis showed bevacizumab-associated side effects were hypertension, proteinurea, gastric/duodenal ulcer, severe bleeding and bowel perforation. No cases of thromboembolic events were detected. |
本系統中英文摘要資訊取自各篇刊載內容。